11 minutes read

China is the only country in the world with HSCT volume on par with the United States — performing 21,714 hematopoietic stem cell transplants in 2023, comparable to US CIBMTR annual volume [1]. More importantly, China’s largest contribution to global HSCT is the Beijing Protocol — the haploidentical hematopoietic stem cell transplant (haplo-HSCT) approach developed by Academician Huang Xiaojun of Peking University People’s Hospital, enabling transplant for patients who don’t have an HLA-matched donor, with long-term survival rates comparable to matched transplant [2]. For international patients, this means: even if no compatible donor can be found in your home country’s bone marrow registry, your parents, siblings, or children can serve as donors in China — at pricing approximately 1/3 to 1/4 of US costs.

What Is Hematopoietic Stem Cell Transplant (HSCT)

Hematopoietic stem cell transplant (HSCT) — commonly known as “bone marrow transplant” — is the core curative therapy for blood cancers, bone marrow failure syndromes, severe immune deficiencies, and certain inherited blood disorders.

Two main categories:

Autologous transplant (auto-HSCT):

  • Uses the patient’s own stem cells
  • Primarily used for multiple myeloma and lymphoma
  • Lower risk (no rejection)
  • Approximately 31% of China’s annual volume

Allogeneic transplant (allo-HSCT):

  • Uses stem cells from another donor
  • Primarily used for acute leukemia, bone marrow failure, immune deficiency
  • Higher risk (rejection, graft-versus-host disease GVHD)
  • Approximately 69% of China’s annual volume

Why Finding a Donor Is the Critical Challenge — Explained Concretely

This is where the most important breakthrough in modern HSCT — and China’s role in it — becomes clear.

HLA: the matching system that determines who can donate to whom

HLA (Human Leukocyte Antigen) is a system of protein markers on the surface of nearly all cells in the body. The immune system uses HLA to distinguish “self” from “non-self.” For HSCT to succeed, the donor’s HLA must match the patient’s well enough that the transplanted immune cells (in the new bone marrow) don’t attack the patient’s body — and the patient’s residual immune system doesn’t reject the transplant.

You inherit HLA from both biological parents — half from your mother (5 markers) and half from your father (5 markers), for a typical total of 10 markers.

Traditional HSCT requires a 10/10 or close match between donor and patient HLA:

  • HLA-identical sibling (10/10 match): each biological sibling has approximately a 1-in-4 (25%) chance of being a perfect match. If you have one sibling, your chance is 25%. With three siblings, it rises to about 58%. Many patients have no siblings or no matching siblings.
  • HLA-matched unrelated donor from a national or international bone marrow registry: depends heavily on ethnic background. In US registries, a Caucasian patient has approximately 75% chance of finding a match; an African American patient has approximately 23%; Asian and mixed-ethnicity patients fall in between. Many patients of ethnic minority or mixed background simply cannot find a match through any registry in the world.

This leaves a large group of patients with no traditional transplant option — and historically, with no curative treatment for diseases like relapsed acute leukemia.

Haploidentical (half-match) HSCT — what changed everything:

In a haploidentical transplant, the donor matches only 5 of 10 HLA markers with the patient. The donor’s other 5 markers come from a different parent than the patient’s.

Critically:

  • A biological parent is automatically a 5/10 match for their child — always
  • A biological child is automatically a 5/10 match for their parent — always
  • Each biological sibling has approximately a 50% chance of being a 5/10 match

This means virtually every patient has access to at least one haploidentical donor — typically a parent, child, or sibling.

The traditional problem with half-match transplants: in the past, half-match transplants caused severe graft-versus-host disease (the donor’s transplanted immune cells attacking the patient’s organs) at very high rates, often fatally. This made half-match transplants impractical for routine use.

Beijing Protocol solved this.

The Beijing Protocol: China’s Breakthrough That Made Half-Match Transplants Mainstream

Core innovation [2]:

  • In 2000, Academician Huang Xiaojun at Peking University People’s Hospital performed the world’s first haploidentical HSCT without ex-vivo T-cell depletion
  • The breakthrough: traditional half-match transplants required physically removing T cells from the donor’s stem cells in a laboratory before infusion (to reduce GVHD) — a costly, complex, and unreliable process that also weakened the transplant’s anti-leukemia effect. Beijing Protocol uses G-CSF + ATG (anti-thymocyte globulin) to modulate donor and recipient immune systems in vivo — no laboratory T-cell removal needed — costs are much lower, GVHD is controlled to rates similar to matched transplants, and the anti-leukemia effect is preserved or strengthened

Clinical data [2]:

  • 5-year overall survival approximately 68%
  • Comparable in efficacy to HLA-matched transplant
  • GVHD rates controlled to comparable levels
  • Long-term relapse rates similar to matched transplant

Global adoption [2]:

  • Adopted by 190+ transplant centers in China
  • Adopted by international centers in Korea, Italy, France, and others
  • Key reviews published in Bone Marrow Transplantation (2019), Haematologica, and other top hematology journals
  • Academician Huang Xiaojun was named honorary member of EBMT (European Society for Blood and Marrow Transplantation) in recognition

Why this matters concretely for international patients:

This is China’s most important differentiating advantage in HSCT — if you or your family member is an HSCT candidate but cannot find an HLA-matched donor in your home country (especially patients of Asian, mixed-ethnicity, or rare HLA backgrounds), the Beijing Protocol allows your parents, siblings, or children to serve as half-matched donors, with outcomes comparable to matched transplant.

This is often the difference between “transplant is possible” and “transplant is impossible” — not just a difference in cost or technique.

China’s HSCT Scale and Global Position

2023 data [1]:

  • 21,714 total HSCT cases
  • Allogeneic: ~15,000 (69%)
  • Haploidentical transplants account for 65% of allogeneic — the dominant donor type in China
  • Autologous: ~6,700 (31%)
  • 212 transplant centers nationwide across 27 provinces

International comparison:

  • US CIBMTR: 22,000–24,000 cases per year
  • European EBMT: ~50,000 cases per year
  • China’s HSCT volume is essentially on par with the US

Key difference:

Dimension China United States
Annual total ~21,700 ~22,000–24,000
Haplo share of allogeneic 65% ~20–30% (growing)
Dominant donor type Haploidentical family member HLA-matched unrelated donor (majority)
International patient experience Growing Established

Important implication: China is the country with the highest proportion, largest case volume, and most mature technical experience in haploidentical transplant in the world — a direct result of Beijing Protocol.

China’s Leading HSCT Centers

Peking University People’s Hospital Hematology Department — Academician Huang Xiaojun / Professor Zhang Xiaohui Team [3]

  • Asia’s largest HSCT center, annual volume 1,200+ cases
  • Beijing Protocol’s birthplace
  • Among the top 5 hematopoietic stem cell transplant centers globally
  • National Clinical Research Center for Hematologic Disorders
  • Extensive international patient experience

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) — Professor Wang Jianxiang Team [4]

  • National Clinical Research Center for Hematologic Disease System
  • Major transplant center (specific annual volume not publicly disclosed)
  • Developed CNCT19 (predecessor of CASI Pharma’s Inaticabtagene autoleucel)

Soochow University 1st Affiliated Hospital — Professor Wu Depei Team

  • Jiangsu Hematology Institute
  • First ASHI-accredited HLA laboratory in China (American Society for Histocompatibility and Immunogenetics) — internationally standard HLA typing capability
  • Major HSCT center

Shanghai Ruijin Hospital Hematology Department — Professor Zhao Weili Team

  • National Translational Medicine Center (Shanghai)
  • Strong in lymphoma and multiple myeloma autologous transplant + CAR-T

Zhejiang University 1st Affiliated Hospital — Professor Huang He Team [5]

  • APBMT (Asia-Pacific Blood and Marrow Transplantation) Executive Board
  • Unrelated donor transplant research awarded second-class National Science and Technology Progress Award
  • Leading in CAR-T + HSCT sequential therapy (see Article 21)

Other significant centers:

  • Huazhong University of Science and Technology Tongji Hospital
  • West China Hospital Hematology
  • Nanfang Hospital (Guangzhou) — particularly strong in thalassemia HSCT for the southern Chinese population

Recommendations for international patients:

  • Complex acute leukemia, pediatric HSCT → Peking University People’s (most Beijing Protocol experience)
  • Difficult HLA matching cases → Soochow 1st (ASHI-accredited HLA lab)
  • CAR-T + HSCT sequential therapy → Zhejiang 1st, Peking University People’s
  • Lymphoma, multiple myeloma → Ruijin, Peking University People’s
  • Thalassemia HSCT → Nanfang Hospital (extensive experience given high thalassemia prevalence in southern China)

HSCT Indications

Acute leukemias (largest category):

  • Acute myeloid leukemia (AML) — China’s #1 HSCT indication (8,419 cases in 2023, 37%) [1]
  • Acute lymphoblastic leukemia (ALL) — #2 (5,164 cases, 23%)

Chronic blood disorders:

  • Chronic myeloid leukemia (CML) — TKI failure or progression
  • Chronic lymphocytic leukemia (CLL)

Bone marrow failure syndromes:

  • Severe aplastic anemia (SAA) — #3 (2,858 cases, 13%)
  • Fanconi anemia
  • Paroxysmal nocturnal hemoglobinuria (PNH)

MDS and myeloproliferative neoplasms:

  • Myelodysplastic syndromes (MDS) — #4 (2,233 cases, 10%)
  • Primary myelofibrosis

Lymphomas and multiple myeloma:

  • Relapsed/refractory Hodgkin lymphoma
  • Relapsed/refractory non-Hodgkin lymphoma
  • Multiple myeloma (typically autologous transplant)

Inherited blood disorders:

  • Thalassemia — #5 (1,316 cases, 6%)
  • Sickle cell disease
  • Severe combined immunodeficiency (SCID)
  • Other inherited bone marrow failure syndromes

Practical implication for international patients: pediatric patients with thalassemia, SCID, Fanconi anemia, and other inherited blood disorders are particularly well-suited to come to China — China has extensive experience, and haploidentical transplant allows parents to serve directly as donors.

Pricing Comparison: China vs the US vs Korea vs India

Country / Region Allogeneic HSCT All-Inclusive Cost (USD)
China (domestic patients) at public hospitals Thalassemia allo ~$36,000; pediatric allo ~$38,500 [6]
China (international patient all-inclusive) $50,000 – $80,000 (includes IMD coordination, English service, haploidentical transplant)
United States $200,000+ (100-day cost $63K–$782K; 1-year cost $69K–$637K)
Korea Starting at ~$70,000
India (HLA-matched allo) $22,000 – $30,000
India (haploidentical allo) $32,000 – $38,000
Singapore $120,000 – $250,000

Sources: CBMTRG, CIBMTR, Mediglobus, BMT Clinic [6]

Core comparison:

  • China all-inclusive is approximately 1/3 to 1/4 of US
  • Comparable pricing to Korea
  • 1.5–2× higher than India, but China’s haploidentical transplant clinical maturity (as the birthplace of Beijing Protocol) and case volume meaningfully exceed India
  • 50–70% less than Singapore

Autologous HSCT pricing: in China approximately $30,000 – $54,000 (CNY 200,000–350,000); in the US typically $100,000+.

International Patient Pathway — A Detailed Walkthrough

Best-suited international patient profile:

  1. Confirmed HSCT indication (especially acute leukemia, SAA, thalassemia, SCID, Fanconi anemia, relapsed lymphoma, etc.)
  2. Cannot find an HLA-matched donor in home country (Asian-background, mixed-ethnicity, or rare HLA type patients especially well-suited)
  3. Home country HSCT wait time is excessive (registry matching can take 3–12 months)
  4. Home country HSCT cost is unaffordable (especially patients without insurance coverage or paying out-of-pocket)
  5. Family members available to serve as haploidentical donors (parents, children, siblings)

Detailed step-by-step pathway:

Phase 1 · Pre-travel evaluation and donor screening (4–6 weeks, remote)

What needs to happen before you travel:

  1. Complete medical records sent to Chinese IMD: pathology, bone marrow biopsy reports, prior treatment history, current laboratory results, complete imaging
  2. HLA typing for patient — if you’ve had this done in your home country, the typed results should be sent; otherwise, blood samples can be analyzed at the Chinese center
  3. HLA typing for all potential family donors — both biological parents (if alive and healthy), all biological children, all biological siblings. Sending typing results allows the Chinese center to identify the optimal haploidentical donor before you travel
  4. Donor health screening — basic medical history, blood pressure, diabetes status, infectious disease screening
  5. Chinese hospital’s hematology MDT review of records, donor candidates, and treatment plan
  6. Cost estimate provided based on confirmed plan and identified donor

Phase 2 · Arrival and complete on-site evaluation (1–2 weeks)

What happens upon arrival:

  1. Patient admission to hospital + complete pre-transplant evaluation: organ function (cardiac, pulmonary, hepatic, renal), infectious disease screening (HIV, HBV, HCV, TB, fungal), psychological evaluation, dental clearance
  2. Donor full evaluation: confirmed HLA typing, detailed health assessment, cardiac/pulmonary evaluation, infectious disease screening, psychological evaluation, ethics committee review of donor’s voluntary consent
  3. Treatment plan finalization with MDT confirmation
  4. Informed consent process (bilingual Chinese-English, with the coordinator’s assistance to ensure full understanding)
  5. Pre-payment of deposit (typically 50–70% of all-inclusive cost — $30,000–$60,000 USD)

Phase 3 · Conditioning chemotherapy (1–2 weeks)

  • “Conditioning” = chemotherapy and/or radiation given to suppress the patient’s existing bone marrow and immune system to make room for the new stem cells
  • Two main protocols:
    • Myeloablative conditioning (high-dose) — for younger, fit patients; typically for active leukemia
    • Reduced-intensity conditioning (lower-dose) — for older or higher-risk patients
  • Patient is in isolation throughout to minimize infection risk

Phase 4 · Donor stem cell collection (1–2 days)

  • Donor receives G-CSF (granulocyte colony-stimulating factor) injections for 4–5 days before collection to mobilize stem cells from bone marrow into bloodstream
  • Collection is done through peripheral blood apheresis (a 4–6 hour procedure, no surgery required in most cases)
  • Donor typically returns to normal activities within 1–2 weeks
  • Donor’s blood counts return to normal within 4–6 weeks

Phase 5 · Stem cell infusion (“Day 0”) and engraftment monitoring (4–6 weeks inpatient)

  • Stem cells are infused intravenously — the procedure itself is straightforward
  • The critical period is the 2–4 weeks while waiting for engraftment (when the donor cells begin producing new blood cells in the patient)
  • During this period: very low white blood cell counts → high infection risk → strict isolation, prophylactic antibiotics/antifungals/antivirals, frequent blood transfusions, daily monitoring
  • Engraftment typically occurs 14–21 days post-infusion
  • Major risks during this phase: infections, bleeding, early acute GVHD, organ toxicity

Phase 6 · Discharge and early follow-up (4–6 weeks in China)

  • Discharge usually 4–6 weeks post-transplant once engraftment is confirmed and the patient is medically stable
  • Stay in a hotel near the hospital with the family donor and any accompanying family
  • Frequent outpatient follow-up (2–3 times per week initially)
  • Anti-rejection medications, anti-infective prophylaxis, blood count monitoring continue

Phase 7 · Return home and long-term remote follow-up (≥2 years)

  • Once stable (typically 100 days post-transplant), the patient returns home
  • Critical step: established coordination with a hematologist in the home country for ongoing management
  • MedCareInChina facilitates handoff and supports remote consultations as needed
  • Continued anti-rejection medication for 6 months to 2 years (gradually tapered)
  • Lifelong long-term monitoring

Total time in China: typically 10–14 weeks (including evaluation, transplant, and early follow-up)

Practical logistics:

  • S1 medical visa (≥180 days) — covers the complete HSCT cycle for the patient
  • Family donor visa (S2) — donor travels with the patient
  • Pre-payment: typically 50–70% of all-inclusive cost, approximately $30,000–$60,000 USD
  • Insurance: some international medical insurance plans (MSH International, Cigna Global, Bupa Global, etc.) cover HSCT — confirm your specific policy’s lifetime cap before traveling

Risks and Side Effects

Major risks:

  1. Graft-versus-host disease (GVHD) — greatest risk of allogeneic transplant
    • Acute GVHD: occurs in 30–60%
    • Chronic GVHD: occurs in 30–50%
    • Severe GVHD mortality approximately 10–20%
  2. Graft failure — approximately 5–10%
  3. Infection — long immunodeficient period (months) after conditioning
  4. Organ toxicity — hepatic, pulmonary, cardiac, renal, neurological
  5. Early mortality: 100-day mortality approximately 10–20% (varies by indication and disease)

Long-term management:

  • Anti-rejection immunosuppression — typically 6 months to 2 years, gradually tapered
  • Long-term infection prevention (vaccinations, prophylactic antibiotics/antivirals)
  • Monitoring for secondary malignancies
  • Chronic GVHD management (if it occurs)

Clinical Data: Outcomes at China’s Leading Centers

Peking University People’s Hospital Beijing Protocol haploidentical transplant [2]:

  • 5-year overall survival approximately 68%
  • Comparable to HLA-matched transplant

Industry-wide outcome data:

  • AML CR1 (first complete remission) post-transplant 5-year OS ~60%
  • ALL CR1 post-transplant 5-year OS ~55%
  • Thalassemia pediatric post-transplant disease-free survival >85%
  • SAA pediatric post-transplant 5-year OS >80%

Comparison with international leading centers: outcomes at China’s leading HSCT centers are on par with Western leading centers, and China leads globally in haploidentical transplant.

Common Questions

I can’t find a matched donor in my home country — can my parents or children really donate to me through Beijing Protocol? Yes. The core breakthrough of Beijing Protocol is enabling haploidentical (half-match) donors to perform HSCT — and your biological parents (100% half-matched), biological children (100% half-matched), and siblings (50% probability of half-matching) all qualify. This is China’s most important differentiating advantage for international patients.

Are haploidentical transplant outcomes really comparable to matched transplant? Yes. Beijing Protocol’s 5-year OS of ~68% is comparable to HLA-matched transplant — published in multiple international top-tier hematology journals.

Is the GVHD risk higher with haploidentical? Beijing Protocol’s GVHD rates are comparable to matched transplant — this is the central technical breakthrough.

Can long-term follow-up after HSCT be done in my home country? Yes. The critical step is establishing immediate post-transplant coordination with your home country HSCT center — MedCareInChina facilitates this. Around 100 days post-transplant, ongoing management typically transfers home.

Can autologous HSCT be done in China? Yes. China’s autologous HSCT experience is also extensive (annual volume ~6,700 cases), primarily used for multiple myeloma and relapsed lymphoma.

If HSCT fails or relapses, can a second transplant be done? Yes, but with higher risk. Second HSCT typically considers a different donor (for example, if a sibling was used first, a parent might be used second).

Pediatric inherited blood disorders (thalassemia, SCID) — how does HSCT in China work? China has extensive experience in pediatric inherited blood disorder HSCT — annual thalassemia HSCT volume in China (1,316 cases) substantially exceeds most Western countries. Nanfang Hospital (Guangzhou), Peking University People’s, and Institute of Hematology and Blood Diseases Hospital (Tianjin) are recognized leading centers.

How long until normal life after HSCT? Typically 6–12 months for gradual recovery of normal life. 1–2 years for most patients to return to work or school. Pediatric patients often recover more quickly.

Bottom Line

The core appeal of HSCT in China:

  • Beijing Protocol haploidentical transplant enables transplant for patients without HLA-matched donors (the central differentiating advantage)
  • Global scale on par with the US — annual volume 21,714 cases
  • Pricing approximately 1/3 to 1/4 of US (international patients $50K–$80K vs US $200K+)
  • International-grade clinical data — 5-year OS 68% with haploidentical, comparable to matched
  • Mature leading centers — Peking University People’s, Soochow 1st, Institute of Hematology Tianjin, and others

Best-suited international patients:

  • Patients with acute leukemia, SAA, MDS, and other blood disorders
  • Patients who cannot find an HLA-matched donor in their home country (China’s most unique HSCT value)
  • Pediatric patients with inherited blood disorders (thalassemia, SCID, Fanconi anemia, etc.)
  • Patients with family members who can serve as haploidentical donors
  • Patients facing unaffordable HSCT costs in their home country

Total time in China: 10–14 weeks (including evaluation, transplant, and early follow-up)

If you or a family member is an HSCT candidate, MedCareInChina can facilitate communication with leading centers including Peking University People’s, Soochow 1st, Institute of Hematology Tianjin, Ruijin, and Zhejiang 1st — assessing HSCT feasibility based on your condition and family situation (especially evaluating the haploidentical donor pathway), with clear judgment on “whether feasible, who would serve as donor, expected timeline, and estimated cost.”

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. China HSCT scale 2023 data — CBMTRG (Chinese Blood and Marrow Transplantation Registry Group) report: 21,714 cases in 2023, allogeneic 69%, haploidentical 65% of allogeneic, covering 212 centers across 27 provinces. Sources: https://pubmed.ncbi.nlm.nih.gov/39322652/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC9481431/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11230778/
  2. Beijing Protocol — Academician Huang Xiaojun at Peking University People’s Hospital performed the world’s first haploidentical HSCT without ex-vivo T-cell depletion in 2000. G-CSF + ATG core protocol. 5-year overall survival approximately 68%. Adopted by 190+ centers in China and international centers in Korea, Italy, France. Key reviews: Bone Marrow Transplantation (2019); Haematologica. Sources: https://pubmed.ncbi.nlm.nih.gov/31431695/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11873716/ ; PKU news: https://newsen.pku.edu.cn/news_events/news/people/14015.html
  3. Peking University People’s Hospital Hematology — Annual volume 1,200+ HSCT cases, Asia’s largest transplant center. Beijing Protocol’s birthplace. Sources: MedBridge https://www.medbridgenz.com/peking-university-peoples-hospital ; Nature https://www.nature.com/articles/d42473-022-00005-4
  4. Institute of Hematology and Blood Diseases Hospital, CAMS (Tianjin) — National Clinical Research Center for Hematologic Disease System. Source: https://en.wikipedia.org/wiki/Institute_of_Hematology_and_Blood_Diseases_Hospital,CAMS%26_PUMC
  5. Zhejiang 1st Hematology Huang He Team — APBMT Executive Board, unrelated donor transplant research awarded second-class National Science and Technology Progress Award. Source: https://www.zju.edu.cn/english/2023/0720/c75130a2785168/page.htm
  6. China HSCT pricing — Thalassemia allo-HSCT average CNY 235,254 ≈ $36,200; pediatric allo-HSCT approximately CNY 250,722 ≈ $38,572. International patient all-inclusive pricing typically $50,000–$80,000. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC10076710/
  7. US HSCT pricing — 100-day cost $63,096–$782,190; 1-year $69,218–$637,193; commonly cited >$200,000. Sources: https://www.sciencedirect.com/science/article/pii/S0006497118490611 ; https://www.astctjournal.org/article/S2666-6367(24)00181-7/pdf
  8. Korea, India, Singapore HSCT pricing — Korea starting at ~$70K; India HLA-matched $22–30K, haploidentical $32–38K; Singapore $120–250K. Sources: Mediglobus https://mediglobus.com/cost-of-bone-marrow-transplantation-and-where-is-it-performed/ ; BMT Clinic India https://bmtclinic.com/treatment/cost-of-bone-marrow-transplant-in-india/
  9. HSCT indication distribution in China (2023) — AML 37% (8,419 cases), ALL 23% (5,164 cases), SAA 13% (2,858 cases), MDS 10% (2,233 cases), thalassemia 6% (1,316 cases). Source: CBMTRG 2023 report https://pubmed.ncbi.nlm.nih.gov/39322652/
  10. HSCT indication international consensus guidelines — China Hematology Society 2021 release. Source: https://link.springer.com/article/10.1186/s13045-021-01159-2